Form 4: enVVeno Director Jenusaitis Granted Stock Options
Insider Transaction Disclosure
enVVeno Medical Corp Director Matthew Jenusaitis was granted 135,883 stock options with an exercise price of $0.325, vesting quarterly throughout 2026.
Summary
- Matthew Jenusaitis, a Director of enVVeno Medical Corp (NVNO), acquired 135,883 stock options.
- The options have an exercise price of $0.325 per share.
- The transaction date for the option grant was December 11, 2025.
- These options were issued under the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended.
- The award is subject to time-based vesting, with equal quarterly installments vesting on the last day of each fiscal quarter during the 2026 calendar year.
- The options have an expiration date of December 11, 2035.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and incentivizing long-term performance. It's a routine compensation event, not indicative of extraordinary news, hence a moderately positive score.
Positives
- The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
- The options were issued under an existing, approved incentive plan, indicating a structured approach to executive compensation.
Future Outlook
The stock options granted to Director Matthew Jenusaitis are subject to time-based vesting, with equal quarterly installments throughout the 2026 calendar year, indicating a future alignment of incentives with company performance over this period.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | Stock options were granted to a director under the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. | 12/11/2025 | This demonstrates the ongoing use of the company's approved incentive plan to compensate and align the interests of its directors with shareholders. |
Stakeholder Impact
- Shareholders: The grant of options to a director aims to align management's long-term interests with shareholder value creation, potentially leading to improved company performance.
- Employees: While this specific grant is to a director, the use of an omnibus incentive plan suggests a broader framework for equity compensation that could extend to other key personnel.
Next Steps
- The stock options will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Key Dates
| Date | Description |
|---|---|
| 12/11/2025 | Date of earliest transaction (stock option grant). |
| 12/15/2025 | Signature date of the reporting person. |
| 2026 | Calendar year during which the stock options will vest in equal quarterly installments. |
| 12/11/2035 | Expiration date of the granted stock options. |
Keywords
enVVeno Medical Corp, NVNO, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting Schedule
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.